Prosecution Insights
Prosecution Insights
19 pending office actions • 12 art units • 19 examiners • 0 of 19 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (32%) |
| §112 only | 2 (11%) |
| Double-patenting only | 2 (11%) |
| Double-patenting + other | 2 (11%) |
| Multi-statute (no §101) | 7 (37%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MISHRA, DEEPA | 1 | 29.5% | +32.2% |
| PERSONS, JENNA L | 1 | 50.0% | +60.0% |
| ROBINSON, HOPE A | 1 | 67.6% | +43.3% |
| GUSTILO, ESTELLA M | 1 | 53.2% | +36.8% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.1% | +29.7% |
| AEDER, SEAN E | 1 | 56.9% | +19.9% |
| WEIDNER, ADAM M | 1 | 63.6% | +34.2% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.5% |
| GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1 | 46.2% | +54.1% |
| MACH, ANDRE | 1 | 45.9% | +53.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268594 | Treatment Schedule for Cytokine Proteins | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 31d overdue |
| 16318895 | Selecting Neoepitopes as Disease-Specific Targets for Therapy with Enhanced Efficacy | GODDARD, LAURA B | 19d |
| 18258343 | Therapeutic RNA for Treating Cancer | PUTTLITZ, KARL J | 26d |
| 17920569 | CORONAVIRUS VACCINE | SPICER, JENINE MARIE | 55d |
| 18837311 | NOVEL THERAPEUTIC USES OF GARDNERELLA ENDOLYSINS | MISHRA, DEEPA | — |
| 18363136 | HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2 | WEIDNER, ADAM M | — |
| 18036676 | ENHANCED FORMULATION STABILIZATION AND IMPROVED LYOPHILIZATION PROCESSES | MACH, ANDRE | — |
| 18036677 | LNP COMPOSITIONS COMPRISING RNA AND METHODS FOR PREPARING, STORING AND USING THE SAME | DACE DENITO, ALEXANDRA GERALDINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268594 | Treatment Schedule for Cytokine Proteins | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 31d overdue |
| 18258343 | Therapeutic RNA for Treating Cancer | PUTTLITZ, KARL J | 26d |
| 18837311 | NOVEL THERAPEUTIC USES OF GARDNERELLA ENDOLYSINS | MISHRA, DEEPA | — |
| 18724236 | LIPID-BASED FORMULATIONS FOR ADMINISTRATION OF RNA | PERSONS, JENNA L | — |
| 18708333 | RNA ENCODING PEPTIDOGLYCAN HYDROLASE AND USE THEREOF FOR TREATING BACTERIAL INFECTION | ROBINSON, HOPE A | — |
| 18696689 | MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY | GUSTILO, ESTELLA M | — |
| 18516006 | Therapeutic RNA | CARTER, SANDRA DILLAHUNT | — |
| 18549346 | MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN THERAPY | AEDER, SEAN E | — |
| Art Unit | Apps |
|---|---|
| 1646 | 2 |
| 1642 | 2 |
| 1615 | 2 |
| 1674 | 2 |
| 1699 | 1 |
| 1652 | 1 |
| 1637 | 1 |
| 1636 | 1 |
| 1644 | 1 |
| 3746 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837311 | NOVEL THERAPEUTIC USES OF GARDNERELLA ENDOLYSINS | MISHRA, DEEPA | — | DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18724236 | LIPID-BASED FORMULATIONS FOR ADMINISTRATION OF RNA | PERSONS, JENNA L | 1699 | DP | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18708333 | RNA ENCODING PEPTIDOGLYCAN HYDROLASE AND USE THEREOF FOR TREATING BACTERIAL INFECTION | ROBINSON, HOPE A | 1652 | §112 | Final Rejection | — | Pending | May 08, 2024 |
| 18696689 | MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY | GUSTILO, ESTELLA M | 1646 | §103 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18516006 | Therapeutic RNA | CARTER, SANDRA DILLAHUNT | — | §112 | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18549346 | MULTISPECIFIC BINDING AGENTS AGAINST CD40 AND CD137 IN THERAPY | AEDER, SEAN E | 1642 | §103 | Non-Final OA | — | Pending | Sep 06, 2023 |
| 18363136 | HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2 | WEIDNER, ADAM M | — | §102§112 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18258343 | Therapeutic RNA for Treating Cancer | PUTTLITZ, KARL J | 1646 | §103§112Other | Final Rejection | 26d | Pending | Jun 20, 2023 |
| 18268594 | Treatment Schedule for Cytokine Proteins | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §102§103 | Non-Final OA | 31d overdue | Pending | Jun 20, 2023 |
| 18036676 | ENHANCED FORMULATION STABILIZATION AND IMPROVED LYOPHILIZATION PROCESSES | MACH, ANDRE | 1615 | §103§112 | Non-Final OA | — | Pending | May 12, 2023 |
| 18036681 | PHARMACEUTICAL COMPOSITIONS COMPRISING PARTICLES AND MRNA AND METHODS FOR PREPARING AND STORING THE SAME | LIPPERT, JOHN WILLIAM | 1615 | §103 | Final Rejection | — | Pending | May 12, 2023 |
| 18036677 | LNP COMPOSITIONS COMPRISING RNA AND METHODS FOR PREPARING, STORING AND USING THE SAME | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §102§103 | Non-Final OA | — | Pending | May 12, 2023 |
| 18035172 | MONOCLONAL ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 PROTEIN AND THEIR USE IN MEDICINE | SKELDING, ZACHARY S | 1644 | §102§103§112DP | Non-Final OA | — | Pending | May 03, 2023 |
| 18180073 | SYSTEMS AND METHODS FOR PRODUCING PHARMACEUTICAL COMPOSITIONS USING PERISTALTIC PUMPS AND DAMPENERS | HERRMANN, JOSEPH S | 3746 | §103 | Final Rejection | 75d | Pending | Mar 07, 2023 |
| 17920569 | CORONAVIRUS VACCINE | SPICER, JENINE MARIE | 3736 | §103§112 | Final Rejection | 55d | Pending | Oct 21, 2022 |
| 17915567 | RNA COMPOSITIONS TARGETING CLAUDIN-18.2 | LI, RUIXIANG | 1674 | §103 | Final Rejection | 67d overdue | Pending | Sep 29, 2022 |
| 17913743 | RNA PARTICLES COMPRISING POLYSARCOSINE | POPA, ILEANA | 1633 | §103Other | Non-Final OA | 60d overdue | Pending | Sep 22, 2022 |
| 17817033 | MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137 | KAUFMAN, CLAIRE M | 1674 | §103DP | Final Rejection | — | Pending | Aug 03, 2022 |
| 16318895 | Selecting Neoepitopes as Disease-Specific Targets for Therapy with Enhanced Efficacy | GODDARD, LAURA B | 1642 | §103§112 | Final Rejection | 19d | Pending | Jan 18, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial